Literature DB >> 23670965

Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.

John M Lachin1.   

Abstract

I describe general expressions for the evaluation of sample size and power for the K group Mantel-logrank test or the Cox proportional hazards (PH) model score test. Under an exponential model, the method of Lachin and Foulkes for the 2 group case is extended to the K ⩾2 group case using the non-centrality parameter of the K - 1 df chi-square test. I also show similar results to apply to the K group score test in a Cox PH model. Lachin and Foulkes employed a truncated exponential distribution to provide for a non-linear rate of enrollment. I present expressions for the mean time of enrollment and the expected follow-up time in the presence of exponential losses to follow-up. When used with the expression for the noncentrality parameter for the test, equations are derived for the evaluation of sample size and power under specific designs with r years of recruitment and T years total duration. I also describe sample size and power for a stratified-adjusted K group test and for the assessment of a group by stratum interaction. Similarly, I describe computations for a stratified-adjusted analysis of a quantitative covariate and a test of a stratum by covariate interaction in the Cox PH model.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Cox proportional hazards model; exponential survival; interactions; logrank test; multiple groups; power; sample size; stratified analysis

Mesh:

Substances:

Year:  2013        PMID: 23670965      PMCID: PMC3775959          DOI: 10.1002/sim.5839

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates.

Authors:  F Y Hsieh; P W Lavori
Journal:  Control Clin Trials       Date:  2000-12

2.  Sample size determination for comparing several survival curves with unequal allocations.

Authors:  Susan Halabi; Bahadur Singh
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

3.  Sample size determination in complex clinical trials comparing more than two groups for survival endpoints.

Authors:  S Ahnn; S J Anderson
Journal:  Stat Med       Date:  1998-11-15       Impact factor: 2.373

4.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

5.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

6.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Authors:  D A Schoenfeld; J R Richter
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

7.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

Authors:  L V Rubinstein; M H Gail; T J Santner
Journal:  J Chronic Dis       Date:  1981

8.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

9.  Sample size requirements for comparing time-to-failure among k treatment groups.

Authors:  R W Makuch; R M Simon
Journal:  J Chronic Dis       Date:  1982

10.  Tables of the number of patients required in clinical trials using the logrank test.

Authors:  L S Freedman
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

View more
  6 in total

1.  Sample size methods for evaluation of predictive biomarkers.

Authors:  Kevin K Dobbin; Lisa M McShane
Journal:  Stat Med       Date:  2022-05-01       Impact factor: 2.497

2.  Design and protocol for a pragmatic randomised study to optimise screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study).

Authors:  Peter MacPherson; Emily L Webb; David G Lalloo; Marriott Nliwasa; Hendramoorthy Maheswaran; Elizabeth Joekes; Dama Phiri; Bertie Squire; Madhukar Pai; Elizabeth L Corbett
Journal:  Wellcome Open Res       Date:  2018-11-21

3.  Loss to follow-up and associated factors among adult people living with HIV at public health facilities in Wakiso district, Uganda: a retrospective cohort study.

Authors:  Denis Opio; Fred C Semitala; Alex Kakeeto; Emmanuel Sendaula; Paul Okimat; Brenda Nakafeero; Joaniter I Nankabirwa; Charles Karamagi; Joan N Kalyango
Journal:  BMC Health Serv Res       Date:  2019-09-04       Impact factor: 2.655

4.  Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China.

Authors:  Feiyun Ouyang; Jun He; Xunjie Cheng; Wei Zhou; Shuiyuan Xiao; Junqun Fang
Journal:  Front Psychiatry       Date:  2022-02-24       Impact factor: 4.157

5.  Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Authors:  L E Selmic; J H Burton; D H Thamm; S J Withrow; S E Lana
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

6.  Strategies for power calculations in predictive biomarker studies in survival data.

Authors:  Dung-Tsa Chen; Po-Yu Huang; Hui-Yi Lin; Eric B Haura; Scott J Antonia; W Douglas Cress; Jhanelle E Gray
Journal:  Oncotarget       Date:  2016-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.